Mass Tort brief
Insurers Settle Delayed Interest as Teva Defends Dual US MDLs
Israel's top insurers resolve a 13-year interest withholding suit as Teva confronts generic price-fixing and Paragard injury dockets in US courts.
Mass Tort
Teva stands as the sole non-settling defendant in the generic price-fixing litigation — confronting jury trials after competitors paid $850M to walk away.
BackgroundThe massive federal litigation in Pennsylvania accuses generic drug manufacturers of entering horizontal price-fixing conspiracies and rigging bids on essential generic medicines. While competitors chose to settle claims, Teva opted to defend against class claims and state enforcement lawsuits.
- A hard consumer claim filing deadline was set for November 9, 2026, as settling manufacturers fund an $850 million restitution pool across 48 states.
- Federal summary judgment rulings upheld per se Sherman Act antitrust liability theories, stripping Teva of key economic justifications for its pricing coordination.
- A pivotal commercial bellwether trial involving private insurer Humana was rescheduled, prolonging legal uncertainty and potential treble damages for Teva's generic division.
Mass Tort
The Supreme Court restricted fast pollution settlements — requiring plaintiffs to prove tangible clean air benefits before collecting legal fees.
BackgroundItem 6 of Israel's Class Actions Law allows citizens to sue industrial enterprises for unlawful air and water emissions under the Clean Air Law. Environmental suits frequently end in withdrawal agreements where plaintiffs collect fees while factories agree to vague operational promises.
- The ruling authored by Justice Ofer Grosskopf establishes that formal withdrawals in environmental torts require rigorous empirical evidence of hazard abatement.
- The underlying case against Arobin Aluminium Industries addressed residential air pollution, where plaintiffs attempted to collect substantial fees despite minimal verified environmental cleanup.
- The decision restricts opportunistic mass tort filings while ensuring industrial polluters face substantive emission enforcement rather than quick monetary settlements.
Mass Tort
A 13-year legal battle forced Israel's top insurers into a ₪100M+ settlement — closing a loop that let carriers pocket interest on delayed payouts.
BackgroundSection 28(a) of Israel's Insurance Contract Law requires carriers to remit statutory linkage and interest on settled claims unpaid past 30 days. Insurers routinely paid principal damages while withholding statutory penalty interest, prompting a series of consolidated class actions in 2013.
- The settlement binds Israel's top five insurance groups—Harel, Clal, The Phoenix, Migdal, and Ayalon—establishing uniform restitution mechanisms across the sector.
- Migdal alone committed to pay ₪56.9 million in historic compensation alongside ₪39.8 million in prospective restitution to affected policyholders, setting the benchmark for peers.
- Carriers must implement automated claims tracking systems across all claims departments, ensuring future delayed payouts automatically trigger statutory penalty interest without customer litigation.
Mass Tort
Teva faces fresh personal injury filings across the 4,000-case Paragard docket — keeping the drugmaker exposed to structural device liability years after divesting.
BackgroundMultidistrict litigation consolidates complex product injury lawsuits nationwide before a single federal judge to streamline pretrial discovery and bellwether test trials. Teva manufactured and distributed the copper device before selling the line to CooperSurgical, while contractually retaining legacy product liability.
- The consolidated docket in Atlanta now exceeds 4,000 active lawsuits alleging the copper implant snaps upon removal, causing uterine perforation and emergency surgery.
- The federal court docketed new personal injury complaints while finalizing pretrial discovery schedules, moving the nine-year dispute closer to first jury trials.
- The renewed filings threaten Teva's balance sheet with protracted settlement demands, just as the generic drugmaker works to trim its heavy post-opioid debt load.
Mass Tort
Mass Tort
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
